First episode psychosis, substance abuse and prognosis: A systematic review

Current Psychiatry Reviews

Volumn 5, Issue 3, 2009, Pages 153-163

  Archie, Suzanne ^a   Gyömörey, Katalin ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Alcohol abuse; Cannabis abuse; First episode psychosis; Outcome studies; Prognosis; Systematic review

Indexed keywords

CANNABIS; COCAINE; PSYCHEDELIC AGENT;

ALCOHOL ABUSE; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HOSPITAL READMISSION; HUMAN; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSITIVE SYNDROME; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; RATING SCALE; RELAPSE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY; SUBSTANCE ABUSE; SYSTEMATIC REVIEW;

EID: 70449578256     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340009788971074     Document Type: Review

References (55)

1. Mueser KT, Yarnold PR, Bellack AS. Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatr Scand 1992; 85(1): 48-55.
2. First M. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV 4th ed. ed. Washington, DC: American Psychiatric Association; 1994.
3. Miles H, Johnson S, Amponsah-Afuwape S, Finch E, Leese M, Thornicroft G. Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder. Psychiatr Serv 2003; 54(4): 554-561 (Pubitemid 36752988)
4. Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia. A prospective community study. J Nerv Ment Dis 1989; 177(7): 408-414
5. Dubertret C, Bidard I, Ades J, Gorwood P. Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. Schizophr Res 2006; 86(1-3): 284-290. (Pubitemid 44234044)
6. Compton MT, Whicker NE, Hochman KM. Alcohol and cannabis use in Urban, African American, first-episode schizophreniaspectrum patients: associations with positive and negative symptoms. J Clin Psychiatry 2007; 68(12): 1939-1945
7. Potvin S, Joyal CC, Pelletier J, Stip E. Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr Res 2008; 100(1-3): 242-251 (Pubitemid 351318147)
8. Hambrecht M, Hafner H. Cannabis, vulnerability and the onset of schizophrenia: an epidemiological perspective. Australian New Zealand J Psychiatry 2000; 34: 468-475. (Pubitemid 30389416)
9. Selten JP, Veen ND, Hoek HW, et al. Early course of schizophrenia in a representative Dutch incidence cohort. Schizophr Res 2007; 97(1-3): 79-87.
10. Barnett JH, Werners U, Secher SM, et al. Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 2007; 190: 515-520 (Pubitemid 46868836)
11. Lambert M, Conus P, Lubman DT, et al. The impact of substance use disorders on clinical outcomes in 643 patients with first episode psychosis. Acta Psychiatrica Scandinavica 2005; 112: 141-148 (Pubitemid 41003193)
12. Archie S, Wilson JH, Woodward K, Hobbs H, Osborne S, McNiven J. Psychotic disorders clinic and first-episode psychosis: a program evaluation. Can J Psychiatry 2005; 50(1): 46-51. (Pubitemid 40238988)
13. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005; 57(10): 1117-1127 (Pubitemid 40615773)
14. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184: 110-117 (Pubitemid 38186851)
15. Degenhardt L, Hall W. The association between psychosis and problematical drug use among Australian adults: findings from the national survey of mental health and well-being. Psychol Med 2001; 31(4): 659-668 (Pubitemid 32421967)
16. van Os J, Bak M, Hanssen M, Bijl R, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002; 156(4): 319-327 (Pubitemid 34857999)
17. Grech A, van Os J, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry Jun 2005; 20(4): 349-353. (Pubitemid 40978562)
18. Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr Bull 2005; 31(3): 608-612 (Pubitemid 41253312)
19. Deas D. Adolescent substance abuse and psychiatric comorbidities. J Clin Psychiatry 2006; 67 (suppl 7): 18-23. (Pubitemid 44378995)
20. Archie S, Rush BR, Akhtar-Danesh N, et al. Substance use and abuse in first-episode psychosis: prevalence before and after early intervention. Schizophr Bull 2007; 33(6): 1354-1363 (Pubitemid 350022769)
21. Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res 2005; 75(1): 135-137 (Pubitemid 40487981)
22. Farrelly S, Harris MG, Henry LP, et al. Prevalence and correlates of comorbidity 8 years after a first psychotic episode. Acta Psychiatr Scand 2007; 116(1): 62-70. (Pubitemid 46889771)
23. Addington J, Addington D. Patterns, predictors, and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatrica Scandinavica 2007; 115: 304-309 (Pubitemid 46425747)
24. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry 2006; 189: 229-234 (Pubitemid 44343467)
25. Wade D, Harrigan S, McGorry PD, Burgess PM, Whelan G. Impact of severity of substance use disorder on symptomatic and functional outcome in young individuals with first-episode psychosis. J Clin Psychiatry 2007; 68(5): 767-774 (Pubitemid 46841862)
26. Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med 2006; 36(10): 1349-1362 (Pubitemid 44355971)
27. Altman D. Systematic reviews of evaluations of prognostic variables. In: Egger M SG, DG Altman, ed. Systematic Reviews in Healthcare: Meta-analysis in context. London: BMJ Pub Group 2007: 211-227
28. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51(4): 273-279
29. Sorbara F, Liraud F, Assens F, Abalan F, Verdoux H. Substance use and the course of early psychosis: a 2-year follow-up of first-admitted subjects. Eur Psychiatry 2003; 18(3): 133-136 (Pubitemid 36644316)
30. Green AI, Tohen MF, Hamer RM, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 2004; 66(2-3): 125-135
31. Kovasznay B, Fleischer J, Tanenberg-Karant M, Jandorf L, Miller AD, Bromet E. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 1997; 23(2): 195-201. (Pubitemid 27224872)
32. Pencer A, Addington J. Substance use and cognition in early psychosis. J Psychiatry Neurosci 2003; 28(1): 48-54. (Pubitemid 36315351)
33. Miller RL. Cannabis: A vulnerability-stress factor in the treatment of recent onset of schizophrenia, schizoaffective disorder, and schizophreniform disorder [Doctorate]: Department of Social Work, Aldelphi University; 2007.
34. Buhler B, Hambrecht M, Loffler W, an der Heiden W, Hafner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse - a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res 2002; 54(3): 243-251
35. Stirling J, White C, Lewis S, et al. Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort. Schizophr Res 2003; 65(2-3): 75-86. (Pubitemid 37434014)
36. Wing J, Cooper J, Sartourius N. Measurement and Classification of Psychiatirc Symptoms: An instruction manual for the PSE and Catego Program. London: Cambridge University Press; 1974.
37. McGorry P, Singh B, Copolov D. Royal Park mulitdiagnostic instrument for psychosis: part II. Development, reliability, and validity. Schizophr Bull 1990; 16: 517-535
38. McGovern M, Morrison D. Chemical use, abuse, and dependence scale (CUAD): rationale, reliability, and validity. Journal of Substance Abuse Treat 1992; 9: 27-37.
39. Williams J, Gibbon M, First M, Spitzer R. The structured clinical interview from DSMIII-R-SCID. Multisite test retest reliability. Arch Gen Psychiatry 1992; 49: 630-635
40. Drake RE, Osher FC, Noordsy D, Hurlbut SC, Teague GB, Beaudett MS. Diagnosis of alcohol use disorders in schizophrenia. Schizophr Bull 1990; 16: 10. (Pubitemid 20110375)
41. Maisto S, Carey M, Carey K, Gordon C, Gleason J. Use of the AUDIT and the DAST to identify alcohol and drug abuse disorder among adults with a severe and persistent mental illness. Psychol Ass 2000; 12(2): 186-192 (Pubitemid 30745971)
42. Mueser KT, Yarnold PR, Rosenberg SD, Swett C, Jr, Miles KM, Hill D. Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups. Schizophr Bull 2000; 26(1): 179-192 (Pubitemid 30317704)
43. Spencer C, Castle D, Michie PT. Motivations that maintain substance use among individuals with psychotic disorders. Schizophr Bull 2002; 28: 233-247 (Pubitemid 35462240)
44. Haro JM, Novick D, Suarez D, Alonso J, Lepine JP, Ratcliffe M. Remission and relapse in the outpatient care of schizophrenia: three-year results from the schizophrenia outpatient health outcomes study. J Clin Psychopharmacol 2006; 26(6): 571-578 (Pubitemid 44772733)
45. Potvin S, Sepehry AA, Stip E. A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychol Med 2006; 36(4): 431-440 (Pubitemid 43380996)
46. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57(6): 594-608. (Pubitemid 40409699)
47. Lysaker P, Bell M, Beam-Goulet J, Milstein R. Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. J Nerv Ment Dis 1994; 182: 109-112 (Pubitemid 24134991)
48. San L, Ciudad A, Alvarez E, Bobes J, Gilaberte I. Symptomatic remission and social / vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study. European Psychiatry. J Ass Eur Psychiatrists 2007; 22(8): 490-498 (Pubitemid 350087651)
49. Soyka M, Albus M, Immler B, Kathmann N, Hippius H. Psychopathology in dual diagnosis and non-addicted schizophrenics: are there differences? Eur Arch Psychiatry Clin Neurosci 2001; 251(5): 232-238
50. Moller T, Linaker OM. Symptoms and life time treatment experiences in psychotic patients with and without substance abuse. Nord J Psychiatry 2004; 58: 237-242 (Pubitemid 38878372)
51. Schwartz RC, Hilscher RL, Hayhow P. Substance abuse and psychosocial impairments among clients with schizophrenia. Am J Orthopsychiatry 2007; 77(4): 610-615 (Pubitemid 351163211)
52. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 2002; 54: 253-264 (Pubitemid 34304218)
53. Swofford C, Scheller-Gilkey G, Miller A, Woolwine B, Mance R. Double jeopardy: schizophrenia and substance use. Am J Drug Alcohol Abuse 2000; 26: 343-353 (Pubitemid 30667001)
54. Potvin S, Pampoulova T, Lipp O, Ait Bentaleb L, Lalonde P, Stip E. Working memory and depressive symptoms in patients with schizophrenia and substance use disorders. Cognit Neuropsychiatry 2008; 13(4): 357-366 (Pubitemid 351990218)
55. Joyal CC, Halle P, Lapierre D, Hodgins S. Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophr Res 2003; 63(3): 297-299 (Pubitemid 37101121)